ClinicalTrials.gg
Not yet recruitingNCT07784049Updated Aug 25, 2026

The Correlation Between Sodium Urate (MSU) Deposition and Coronary Atherosclerosis in Patients With Foot Gout

An observational study in Gout and Coronary Atheroma, sponsored by The Affiliated Hospital of Qingdao University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by The Affiliated Hospital of Qingdao University · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This observational study aims to evaluate the association between sodium urate deposition volume and coronary atherosclerotic plaques in patients with foot gout using dual-energy CT (DECT) and coronary CTA. This study will explore imaging-based evidence for the progression and risk prediction of adverse cardiovascular events in patients with gout.

Read the detailed description

Gout is a common form of inflammatory arthritis characterized by the deposition of monosodium urate crystals in joints and other tissues. This condition triggers an acute inflammatory response; over time, it can increase the incidence and disability associated with chronic gout. Beyond the musculoskeletal system, gout is also linked to an elevated risk of cardiovascular diseases (e.g., coronary artery disease). Chronic inflammation and endothelial dysfunction are the primary mechanisms underlying this association. In recent years, dual-energy computed tomography (DECT) has enabled the direct detection of MSU deposits in the ankle joint and coronary artery walls, which may serve as one of the driving factors for plaque inflammation and rupture. DECT utilizes distinct energy absorption spectra to differentiate MSU deposits from other substances, providing an non-invasive method for assessing the extent of MSU crystal deposition. It has been demonstrated that DECT can be accurately employed to identify MSU deposits within larger anatomical structures-such as urate crystals in peripheral joints-as well as to detect MSU within coronary artery plaques. In conclusion, monitoring the relationship between gout burden and the severity of atherosclerosis in patients with podagra can serve as an imaging-based reference for predicting the risk of cardiovascular adverse events in these patients.

02

Conditions studied

  • Gout
  • Coronary Atheroma
03

In context

Gout

345 studies on the registry are indexed under Gout; 49 are open to participants now.

This study's planned enrollment of 200 is below the median of 232 across 52 observational studies indexed under Gout.

Browse Gout studies →

Lead sponsor

The Affiliated Hospital of Qingdao University is the lead sponsor of 149 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with podagra who have high-risk factors for cardiovascular disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years, male or female
  • Clinically diagnosed with podagra
  • Having high-risk factors for cardiovascular disease
  • Complete clinical data available
  • Patients and their family members are informed, consent and have signed the form

Exclusion criteria

Exclusion Criteria:

  • Women who are preparing for pregnancy, pregnant or breastfeeding
  • Male and female subjects of reproductive age who are unable to take effective measures
  • Patients who cannot or are unable to undergo CTA scans
  • Patients with severe heart diseases such as severe heart failure, severe heart valve disease and cardiomyopathy
  • Severe hemodynamic instability
  • Any other reason making subjects unsuitable to participate in the study, including subjects who are unable or unwilling to comply with the requirements of the study protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testDECT;CCTA

    Perform DECT and CCTA examinations on the patient

06

What researchers measure

Primary outcomes

  1. Volume of sodium urate deposition and coronary artery plaque volume

    Measurement of sodium urate deposition volume and coronary artery plaque volume in patients with foot gout.

    Time frame: baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07784049
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Aug 20, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Aug 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion